132 related articles for article (PubMed ID: 38609747)
1. Sequential endoluminal gemcitabine and docetaxel vs. Bacillus Calmette-Guérin for the treatment of upper tract carcinoma in situ.
McElree IM; Mott SL; Hougen HY; Packiam VT; O'Donnell MA; Steinberg RL
Urol Oncol; 2024 Jul; 42(7):221.e9-221.e16. PubMed ID: 38609747
[TBL] [Abstract][Full Text] [Related]
2. Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.
Steinberg RL; Packiam VT; Thomas LJ; Brooks N; Vitale A; Mott SL; Crump T; Wang J; DeWolf WC; Lamm DL; Kates M; Hyndman ME; Kamat AM; Bivalacqua TJ; Nepple KG; O'Donnell MA
Urol Oncol; 2022 Jan; 40(1):9.e1-9.e7. PubMed ID: 34092482
[TBL] [Abstract][Full Text] [Related]
3. Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
McElree IM; Steinberg RL; Martin AC; Richards J; Mott SL; Gellhaus PT; Nepple KG; O'Donnell MA; Packiam VT
J Urol; 2022 Sep; 208(3):589-599. PubMed ID: 35892270
[TBL] [Abstract][Full Text] [Related]
4. Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma.
McElree IM; Belzer A; Mott SL; Packiam VT; O'Donnell MA; Steinberg RL
Urol Oncol; 2024 Jan; 42(1):20.e9-20.e15. PubMed ID: 37805338
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer.
Daniels MJ; Barry E; Milbar N; Schoenberg M; Bivalacqua TJ; Sankin A; Kates M
Urol Oncol; 2020 Feb; 38(2):40.e17-40.e24. PubMed ID: 31473090
[TBL] [Abstract][Full Text] [Related]
6. Induction and maintenance of sequential intravesical gemcitabine/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols.
Ben-David R; Tillu N; Alerasool P; Bieber C; Ranti D; Tolani S; Eisenhauer J; Chung R; Lavallée E; Waingankar N; Attalla K; Wiklund P; Mehrazin R; Anderson CB; Sfakianos JP
World J Urol; 2024 May; 42(1):315. PubMed ID: 38734774
[TBL] [Abstract][Full Text] [Related]
7. Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study.
Pareek T; Parmar K; Sharma AP; Kumar S
Urol Int; 2022; 106(8):784-790. PubMed ID: 35654025
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer.
Chevuru PT; McElree IM; Mott SL; Steinberg RL; O'Donnell MA; Packiam VT
Urol Oncol; 2023 Mar; 41(3):148.e1-148.e7. PubMed ID: 36456454
[TBL] [Abstract][Full Text] [Related]
9. Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy.
Yim K; Melnick K; Mott SL; Carvalho FLF; Zafar A; Clinton TN; Mossanen M; Steele GS; Hirsch M; Rizzo N; Wu CL; Mouw KW; Wszolek M; Salari K; Feldman A; Kibel AS; O'Donnell MA; Preston MA
Urol Oncol; 2023 Nov; 41(11):458.e1-458.e7. PubMed ID: 37690933
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of intrarenal Bacillus Calmette-Guérin/interferon-α2B for biopsy-proven upper-tract carcinoma in situ.
Shapiro EY; Lipsky MJ; Cha DY; McKiernan JM; Benson MC; Gupta M
J Endourol; 2012 Dec; 26(12):1645-50. PubMed ID: 22834939
[TBL] [Abstract][Full Text] [Related]
11. Sequential intravesical gemcitabine and docetaxel for treatment-naïve and previously treated intermediate-risk nonmuscle invasive bladder cancer.
McElree IM; Orzel J; Stubbee R; Steinberg RL; Mott SL; O'Donnell MA; Packiam VT
Urol Oncol; 2023 Dec; 41(12):485.e1-485.e7. PubMed ID: 37442741
[TBL] [Abstract][Full Text] [Related]
12. Management of primary upper urinary tract carcinoma in situ diagnosed by ureteroscopic biopsy: Is bacillus Calmette-Guerin an alternative to nephroureterectomy?
Territo A; Fontanet S; Meneghetti I; Gallioli A; Sanguedolce F; Rodriguez-Faba Ó; Gaya JM; Palou J; Huguet J; Breda A
Actas Urol Esp (Engl Ed); 2023 May; 47(4):221-228. PubMed ID: 36379260
[TBL] [Abstract][Full Text] [Related]
13. Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?
Abou Chakra M; Packiam VT; Duquesne I; Peyromaure M; McElree IM; O'Donnell MA
Expert Opin Pharmacother; 2024 Feb; 25(2):203-214. PubMed ID: 38264853
[TBL] [Abstract][Full Text] [Related]
14. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
[TBL] [Abstract][Full Text] [Related]
15. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer.
Tan WS; McElree IM; Davaro F; Steinberg RL; Bree K; Navai N; Dinney CP; O'Donnell MA; Li R; Kamat AM; Packiam VT
Eur Urol Oncol; 2023 Oct; 6(5):531-534. PubMed ID: 37468392
[TBL] [Abstract][Full Text] [Related]
16. Early experience with sequential intravesical gemcitabine and docetaxel for micropapillary variant non-muscle invasive bladder cancer.
Abou Chakra M; McElree IM; Packiam VT; Mott SL; O'Donnell MA
Urol Oncol; 2024 May; ():. PubMed ID: 38796357
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer.
McElree IM; Steinberg RL; Mott SL; O'Donnell MA; Packiam VT
JAMA Netw Open; 2023 Feb; 6(2):e230849. PubMed ID: 36853609
[TBL] [Abstract][Full Text] [Related]
18. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.
Skinner EC; Goldman B; Sakr WA; Petrylak DP; Lenz HJ; Lee CT; Wilson SS; Benson M; Lerner SP; Tangen CM; Thompson IM
J Urol; 2013 Oct; 190(4):1200-4. PubMed ID: 23597452
[TBL] [Abstract][Full Text] [Related]
19. Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery.
Thalmann GN; Markwalder R; Walter B; Studer UE
J Urol; 2002 Oct; 168(4 Pt 1):1381-5. PubMed ID: 12352398
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
DeCastro GJ; Sui W; Pak JS; Lee SM; Holder D; Kates MM; Virk RK; Drake CG; Anderson CB; James B; Abate-Shen CT; McKiernan JM
J Urol; 2020 Aug; 204(2):247-253. PubMed ID: 32118506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
